|
07-28-2021, 09:11 PM,
|
|
|
Stella01
|
Berichten: 2
2
Lid sinds: May 2021
Reputatie:
0
|
|
Cancer Biomarkers Market share will expand till 2030
Roots Analysis is pleased to announce the publication of its recent study, titled, “Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2021–2030.”
The report features an extensive study of the current landscape and future outlook of the immuno-oncology biomarkers testing market (focusing particularly on TMB, MSI and TILs (CD3+, CD4+, CD8+, FOXP3+)). It provides an in-depth analysis, highlighting the capabilities of the various companies engaged in this domain. Amongst various elements, the report includes:
· A detailed analysis of ongoing, biomarker-based clinical trials initiated by big pharmaceutical companies.
· An analysis of the landscape of companies offering testing services for cancer biomarkers, namely TMB, MSI / MMR and TILs (including CD3+, CD4+, CD8+ and FOXP3+).
· An insightful 2X2 representation of the results of a detailed competitiveness analysis of various tests (segregated across different biomarker groups).
· Elaborate profiles of leading analytical testing service providers focused on immuno-oncology biomarkers (shortlisted based on strength of service portfolio).
· A detailed publication analysis of over 180 research articles that have been published since 2016, highlighting the key focus areas of ongoing research activity related to immuno-oncology biomarkers, namely TMB, MSI / MMR and TILs.
· A comprehensive clinical trial analysis of completed, ongoing and planned studies, focused on the assessment of cancer biomarkers, namely TMB, MSI / MMR and TILs.
· A discussion on the upcoming opportunities that are likely to impact the evolution of this market over the coming years.
· A discussion on various steps involved in development operations of companion diagnostics
· A comparative analysis of the needs of different stakeholders involved in the development of companion diagnostic products.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Request for Customization:
https://www.rootsanalysis.com/reports/253/request-customization.html
Type of test
· Laboratory Developed Tests (LDTs)
· Companion Diagnostic Tests (CDx)
Type of disease indication
· Breast cancer
· Blood cancer
· Colon / Colorectal cancer
· Lung Cancer
· Melanoma
· Prostate Cancer
Type of cancer biomarker
· TMB
· MSI / MMR
· TILs
Type of analytical technique
· Next Generation Sequencing (NGS)
· Polymerase Chain Reaction (PCR)
· Immunohistochemistry (IHC)
· Others
Key geographical regions
· North America
· Europe
· Japan
· China
· Australia
Key companies covered in the report
· Foundation Medicine
· NeoGenomics Laboratories
· Novogene
· Q2 Solutions
· Personal Genome Diagnostics
· Dr Lal Path Labs
· Shenzhen Yuce Biotechnology
Inquiry before Purchasing:
https://www.rootsanalysis.com/reports/253/request-sample.html
Please Visit Our Upcoming Reports
|
|
|
|
Cancer Biomarkers Market share will expand till 2030
